AAPG 6-K/A
Ascentage Pharma Group International (AAPG)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K/A
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of March 2025
Commission File Number: 002-023311
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
This report on Form 6-K/A is being filed by Ascentage Pharma Group International (the “Company”) to amend the Form 6-K filed with the Commission on March 25, 2025, as the Hong Kong Stock Exchange Voluntary Announcement entitled “ASCENTAGE PHARMA TO PRESENT FIVE PRECLINICAL STUDIES FROM INNOVATIVE PIPELINE AT AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) ANNUAL MEETING 2025” was inadvertently not attached to the Form 6-K. We have corrected the 6-K by attaching the Hong Kong Stock Exchange Voluntary Announcement. Other than this correction, there are no other changes or amendments to the Form 6-K as originally filed.
1
INDEX TO EXHIBITS
| Exhibit<br>Number | Exhibit<br>Title | |
|---|---|---|
| 99.1 | Press Release dated March 25, 2025 | |
| 99.2 | Hong Kong Stock Exchange Voluntary Announcement dated March 26, 2025 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ASCENTAGE<br>PHARMA GROUP INTERNATIONAL | |
|---|---|
| Date: March 26, 2025 | /s/<br>Dajun Yang |
| Name: Dajun Yang | |
| Title: Chief<br>Executive Officer |
3
Exhibit 99.1
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
ROCKVILLE, MD, and SUZHOU, China, March 25, 2025—Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that five abstracts highlighting the latest preclinical results from its pipeline programs have been selected for presentations at the 2025 American Association of Cancer Research Annual Meeting (AACR), taking place April 25-30, 2025, in Chicago, Illinois, USA.
The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, EED inhibitor APG-5918, and IAP antagonist AS03157.
The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science and medicine.
The five preclinical abstracts from Ascentage Pharma include:
Olverembatinib (HQP1351) in combination with lisaftoclax (APG-2575) overcomes venetoclax resistance in preclinical models of acute myeloid leukemia (AML)
| ● | Abstract#: 5652 | |
|---|---|---|
| ● | Session Category: Experimental and Molecular Therapeutics | |
| --- | --- | --- |
| ● | Session Title: Novel Antitumor Agents 3 | |
| --- | --- | --- |
| ● | Date and Time: Tuesday April 29, 2025, 2:00 PM –<br>5:00 PM, Central Time (Wednesday April 30, 2025, 3:00 AM – 6:00 AM, Beijing Time) | |
| --- | --- | --- |
Effects of olverembatinib (HQP1351) in combination with BCL-2 inhibitor lisaftoclax (APG-2575) in T-cell acute lymphoblastic leukemia (T-ALL)
| ● | Abstract#: 5648 | |
|---|---|---|
| ● | Session Category: Experimental and Molecular Therapeutics | |
| --- | --- | --- |
| ● | Session Title: Novel Antitumor Agents 3 | |
| --- | --- | --- |
| ● | Date and Time: Tuesday April 29, 2025, 2:00 PM –<br>5:00 PM, Central Time (Wednesday April 30, 2025, 3:00 AM – 6:00 AM, Beijing Time | |
| --- | --- | --- |
Embryonic ectoderm development protein (EED) inhibitor APG-5918 exhibits potent antitumor activity and synergizes with androgen receptor (AR) inhibitor enzalutamide in preclinical prostate cancer (PCa) models
| ● | Abstract#: 446 | |
|---|---|---|
| ● | Session Category: Experimental<br>and Molecular Therapeutics | |
| --- | --- | --- |
| ● | Session Title: Epigenetic Targets | |
| --- | --- | --- |
| ● | Date and Time: Sunday April<br>27, 2025, 2:00 PM – 5:00 PM, Central Time (Monday April 28, 2025, 3:00 AM – 6:00 AM, Beijing Time) | |
| --- | --- | --- |
APG-2449, a novel focal adhesion kinase (FAK) inhibitor, enhances the antitumor activity of chemotherapy in preclinical models of small-cell lung cancer (SCLC) with activated FAK
| ● | Abstract#: 1679 | |
|---|---|---|
| ● | Session Category: Experimental<br>and Molecular Therapeutics | |
| --- | --- | --- |
| ● | Session Title: Drug Combination<br>Strategies for Cancer Treatment | |
| --- | --- | --- |
| ● | Date and Time: Monday April<br>28, 2025, 9:00 AM – 12:00 PM, Central Time (Monday April 28, 2025, 10:00 PM – 1:00 AM the next day, Beijing Time) | |
| --- | --- | --- |
Discovery of AS03157 as a highly potent and orally active antagonist of inhibitor of apoptosis proteins (IAPs)
| ● | Abstract#: 5651 | |
|---|---|---|
| ● | Session Category: Experimental<br>and Molecular Therapeutics | |
| --- | --- | --- |
| ● | Session Title: Novel Antitumor<br>Agents 3 | |
| --- | --- | --- |
| ● | Date and Time: Tuesday April<br>29, 2025, 2:00 PM – 5:00 PM, Central Time (Wednesday April 30, 2025, 3:00 AM – 6:00 AM, Beijing Time) | |
| --- | --- | --- |
Olverembatinib is an investigational drug and is not approved in the U.S.
2
About Ascentage Pharma
Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market under the ticker symbol “AAPG” since January 2025.
The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53; and next-generation TKIs that target kinase mutants emergent during cancer treatment. Ascentage Pharma is also the only company in the world with active clinical programs targeting all known key apoptosis regulators. The company has conducted more than 40 clinical trials in the US, Australia, Europe, and China, including 11 completed or ongoing US/global registrational trials on the company’s 5 key clinical-stage assets, of which 2 trials are regulated by the US FDA.
Olverembatinib, one of the company’s lead assets, is already approved in China with all of its approved indications included into the China National Reimbursement Drug List (NRDL). Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the Priority Review designation by the China CDE.
To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies such as Takeda, AstraZeneca, Merck, Pfizer and Innovent; and research and development relationships with leading research institutions such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan.
The company has built a talented team with a wealth of global experience in the discovery and development of innovative drugs and fully functional commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.
3
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
+86 512 85557777
Stephanie Carrington
ICR Healthcare
(646) 277-1282
Media Relations
Sean Leous
ICR Healthcare
(646) 866-4012
4
Exhibit 99.2
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
ASCENTAGE PHARMA GROUP INTERNATIONAL
亞 盛 醫 藥 集 團
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6855)
VOLUNTARY ANNOUNCEMENT
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
Ascentage Pharma Group International (the “Company” or “Ascentage Pharma”) is pleased to announce that five abstracts highlighting the latest preclinical results from its pipeline programs have been selected for presentations at the 2025 American Association of Cancer Research Annual Meeting (AACR), taking place April 25, 2025 to April 30, 2025, in Chicago, Illinois, USA.
The data to be presented encompasses five of the Company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ ALK/ROS1 tyrosine kinase inhibitor APG-2449, EED inhibitor APG-5918, and IAP antagonist AS03157.
The five preclinical abstracts from Ascentage Pharma include:
Olverembatinib (HQP1351) in combination with lisaftoclax (APG-2575) overcomes venetoclax resistance in preclinical models of acute myeloid leukemia (AML)
| ● | Abstract<br>number: 5652 |
|---|---|
| ● | Session<br>Category: Experimental and Molecular Therapeutics |
| --- | --- |
| ● | Session<br>Title: Novel Antitumor Agents 3 |
| --- | --- |
| ● | Date<br>and Time: Tuesday April 29, 2025, 2:00 PM – 5:00 PM, USA Central Time (Wednesday April<br>30, 2025, 3:00 AM – 6:00 AM, Beijing Time) |
| --- | --- |
Effects of olverembatinib (HQP1351) in combination with BCL-2 inhibitor lisaftoclax (APG-2575) in T-cell acute lymphoblastic leukemia (T-ALL)
| ● | Abstract<br>number: 5648 |
|---|---|
| ● | Session<br>Category: Experimental and Molecular Therapeutics |
| --- | --- |
| ● | Session<br>Title: Novel Antitumor Agents 3 |
| --- | --- |
| ● | Date<br>and Time: Tuesday April 29, 2025, 2:00 PM – 5:00 PM, USA Central Time (Wednesday April<br>30, 2025, 3:00 AM – 6:00 AM, Beijing Time) |
| --- | --- |
Embryonic ectoderm development protein (EED) inhibitor APG-5918 exhibits potent antitumor activity and synergizes with androgen receptor (AR) inhibitor enzalutamide in preclinical prostate cancer (PCa) models
| ● | Abstract<br>number: 446 |
|---|---|
| ● | Session<br>Category: Experimental and Molecular Therapeutics |
| --- | --- |
| ● | Session<br>Title: Epigenetic Targets |
| --- | --- |
| ● | Date<br>and Time: Sunday April 27, 2025, 2:00 PM – 5:00 PM, USA Central Time (Monday April<br>28, 2025, 3:00 AM – 6:00 AM, Beijing Time) |
| --- | --- |
APG-2449, a novel focal adhesion kinase (FAK) inhibitor, enhances the antitumor activity of chemotherapy in preclinical models of small-cell lung cancer (SCLC) with activated FAK
| ● | Abstract<br>number: 1679 |
|---|---|
| ● | Session<br>Category: Experimental and Molecular Therapeutics |
| --- | --- |
| ● | Session<br>Title: Drug Combination Strategies for Cancer Treatment |
| --- | --- |
| ● | Date<br>and Time: Monday April 28, 2025, 9:00 AM – 12:00 PM, USA Central Time (Monday April<br>28, 2025, 10:00 PM – 1:00 AM the next day, Beijing Time) |
| --- | --- |
2
Discovery of AS03157 as a highly potent and orally active antagonist of inhibitor of apoptosis proteins (IAPs)
| ● | Abstract<br>number: 5651 |
|---|---|
| ● | Session<br>Category: Experimental and Molecular Therapeutics |
| --- | --- |
| ● | Session<br>Title: Novel Antitumor Agents 3 |
| --- | --- |
| ● | Date<br>and Time: Tuesday April 29, 2025, 2:00 PM – 5:00 PM, USA Central Time (Wednesday April<br>30, 2025, 3:00 AM – 6:00 AM, Beijing Time) |
| --- | --- |
Olverembatinib is an investigational drug and is not approved in the U.S.
Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market APG-2575, APG-2449, APG-5918 and AS03157 successfully.
| By order of the Board | |
|---|---|
| Ascentage Pharma Group International<br><br>Dr. Yang Dajun | |
| Chairman and Executive Director |
Suzhou, People’s Republic of China, March 26, 2025
As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei and Dr. David Sidransky and Ms. Marina S. Bozilenko and Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.
3